Yaz Articles

Patent briefs: Yaz patent invalid; FDA bars generic OxyContin; Appeals court backs GSK over Arzerra

17 April 2013

Bayer updates drospirenone-containing COCs labels to reflect VTE risk

11 April 2012

Mixed views on drospirenone OCs

9 December 2011

US FDA communicates concern about drospirenone-containing birth control pills

27 September 2011

Two new studies find Bayer's contraceptives Yaz and Yasmin have an increased risk of blood clots

26 April 2011

Teva admits to making false statements in US copy version of Bayer’s YAZ, Gianvi, label and agrees to corrective measures

18 June 2010

Teva launches generic Yaz in USA, breaking deal with Bayer, which says it will sue; Mylan’s generic Valtrex OKed by FDA

2 June 2010

Bayer outperforms expectations for 2009, but 4th quarter and guidance disappoints

1 March 2010

Teva returns to profit, as 4th quarter 2009 sales leap 33%

16 February 2010

Teva reports 25% sales leap for 3rd quarter 2009, boosted by Copaxone

4 November 2009

Bayer claims it is “back on the uptrend,” but 3rd quarter 2009 sales drop 7%

27 October 2009

Swissmedic backs safety of hormonal contraceptives containing drospirenone

23 October 2009

Teva's 1st-qtr profit more than triples

6 May 2009

Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well

29 April 2009

Teva gets FDA appro for generic Yaz

3 April 2009

Bayer profit down 63% on restructuring and acquisition charges, despite higher sales

9 March 2009

Bayer must retract television adverts for Yaz to settle law suit

16 February 2009

Bayer updates press on current pipeline

12 January 2009

"We're on track," says Bayer chairman, despite 76% profit plunge in 3rd qtr

3 November 2008

Barr's 2nd-qtr 2008 profit rises 27%

18 August 2008

Bayer's 2nd-qtr 2008 net profit falls 13%

11 August 2008

Teva bids $7.46 billion for Barr, whose shares leapt to two-year high on rumors

28 July 2008

Bayer enters generic Yasmin deal with Barr

30 June 2008

Stock Commentary - New York week to May 26, 2008

2 June 2008

Bayer Schering to market Yaz in EU

12 May 2008

Bayer's 1st-qtr net profit reaches $1.21B, HealthCare unit bolsterd by drug sales

5 May 2008

Bayer files patent infringement lawsuit against Watson and Sandoz over Yasmin

28 April 2008

Stock Commentary - Europe - week to March 10, 2008

17 March 2008

Stock Commentary - New York week to March 10, 2008

17 March 2008

US court rules patent for Yasmin is invalid

10 March 2008

Bayer's 4th-qtr 2007 profit plummets 76% to 67M euros, well below analyst expectations

10 March 2008

Watson files ANDA for generic of Bayer-Schering's Yaz

19 November 2007

Bayer beats forecasts, helped by a tax gain, and leads markets higher

12 November 2007

Bayer Healthcare gets big boost from Schering as 2nd-qtr net leaps 46%

13 August 2007

UPDATE: Cancer drugs, OCs and Schering boost Bayer's 2nd-qtr, as group net leaps 46%

13 August 2007

Yaz approved in the Netherlands

16 July 2007

Bayer and Intendis to promote Yaz for acne

14 May 2007

Bayer's 1st-qtr 2007 sales rise 23% to $11.3B

7 May 2007

Bayer AG 4th-qtr profits surge, boosted by health care business and Schering AG

26 March 2007

Yaz cleared for acne by the FDA

5 February 2007

Bayer's 3rd-qtr income down 35% on Schering AG buy, while sales climb 26%

4 December 2006

Schering AG buy boosts Bayer but charges take toll on profit; 3rd-qtr beats forecasts

4 December 2006

Bayer/Schering AG present R&D pipeline, highlighting Nexavar, Campath and Yaz

6 November 2006

FDA OKs new indiction for Schering AG's YAZ

9 October 2006

Takeover costs impact Schering AG's 1st-half 2006

31 July 2006

Takeover costs impact Schering's 1st-half 2006

26 July 2006

Germany's Schering AG sees 1st-qtr 2006 net sales growth of 16% to 1.41 billion euros

1 May 2006

16% 1st-qtr 2006 sales rise for Schering AG

24 April 2006

Warner Chilcott's files patent suit against makers of Yaz

3 April 2006

Schering AG's Yaz gets FDA go ahead

27 March 2006

Merck KGaA makes hostile 14.6 billion-euro bid for Schering AG, which snubs it

20 March 2006

Schering AG sees 2005 net leap 23%

27 February 2006

US FDA gives tentative OK for Schering's Yaz in PMDD

30 January 2006

FDA extends review of Schering's Yaz NDA

19 December 2005

Schering AG gets approval in the Netherlands for Yasminelle

22 August 2005

Schering AG 1st-half profits leap 23%

1 August 2005

Schering AG commits to operating margin of 16% this year and 18% in 2006

4 July 2005

Schering AG opens Asia-Pacific HQ in Singapore

20 June 2005

Schering AG files patent law suit against Barr over Yasmin

9 May 2005

Schering AG sees 1st-qtr net profit rise 11%, with strong sales growth in USA

25 April 2005

Barr confirms filing in USA for Yasmin

4 April 2005

Schering AG's Yasmin under pressure in USA

28 March 2005

Schering AG says it has set course for growth with good 2004 results

14 March 2005

Weak $ takes its toll on Schering AG's 4th-qtr sales, but profit rises 23%

14 February 2005

FDA approvable letter for Schering AG's Yaz

22 November 2004

Schering AG's three-qtr EPS rises 12%

25 October 2004

Additional patent for Schering AG's Yasmin

20 September 2004

Schering AG raises 2004 forecast on 2nd-qtr

2 August 2004

Schering-AG's low-dose Yasmin delayed

26 July 2004

Schering AG reveals restructuring to focus on oncology and gynecology

21 June 2004

Letter from the Editor

21 June 2004

Schering AG's 1st-qtr beats expectations

3 May 2004

UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook

16 February 2004

Schering AG reports 6% "organic" sales growth for 2003

9 February 2004

Schering AG files NDA for low-dose Yasmin

22 December 2003

Schering AG sees strong profit growth

3 November 2003

Indian pharmaceutical news in brief

13 October 2003

Profits and sales down at Schering AG

11 August 2003

Schering AG's Leukine may compensate for Yasmin generics, says Morgan Stanley

4 August 2003

UPDATE: Galen merger talks with Barr terminated as share price is driven higher

28 July 2003

Galen Merger talks terminated

28 July 2003

Schering AG's R&D day impressive, but doubts over short term, say analysts

7 July 2003

Schering AG beats forecasts in 2002

10 March 2003

Update: Sales up 11% at Schering AG

10 March 2003

Schering AG's 2002 sales disappoint

10 February 2003

D&TB dismisses weight-neutral claims for Yasmin

19 August 2002

Schering AG US sales up 22% in Q2

5 August 2002

Schering AG's 1st-qtr sales rise 7%

6 May 2002

Yasmin under fire in the Netherlands?

29 April 2002

Schering AG CEO optimistic about firm's future prospects

22 April 2002

Schering's Yasmin launched in UK

22 April 2002

Germany's Schering AG outlines prospects for future growth

11 March 2002

Net income up 24% at Schering AG as Betaferon sales stay strong

11 February 2002

Net profit in 2002 should reach 1.1 billion euros at Schering AG

7 January 2002

Net income up 23% at Schering AG as Betaferon sales stay strong

9 November 2001

Schering AG's Yasmin for severe PMS?

23 August 2001

Schering AG raises earnings expectations

27 July 2001

Schering AG launches Yasmin OC in USA

26 June 2001

Schering AG acquires 24.5% of Molypharma

1 June 2001

Schering AG's Yasmin registered in USA

21 May 2001

Showing 1-100 of 111 articles

Go to beginningPreviousNextGo to end